The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world's leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP). The addition of this latest recombinant protein expands the Company's comprehensive portfolio of antigens and antibodies for infectious diseases and has been designed to support immunoassay and vaccine development.

Sudan Ebolavirus is a species of ebolavirus responsible for severe disease in humans, Ebola haemorrhagic fever, for which there are currently no licensed vaccines or treatments available. In total, six Sudan Ebolavirus outbreaks have been documented, most recently in Uganda, where there have been 141 confirmed cases of the virus, with a mortality rate of 39%*. The Native Antigen Companyís SEBOV GP is designed for use in immunoassay and vaccine development to support research into the deadly disease.

The Companyís recombinant SEBOV GP was expressed in HEK293 cells and features a C-terminal His-tag, with secretion driven by a heterologous signal peptide. The glycoprotein is responsible for attachment, fusion and entry of the virus to target cells, as well as critical pathogenic differences among viral species. The function of the EBOV GP makes it a vital component of vaccines and a prime target of neutralizing antibodies, and inhibitors of attachment and fusion.

Pardeep Sharda, Senior Product Manager, The Native Antigen Company, said:

The new SEBOV GP product builds on our recognized expertise in infectious diseases, expanding our portfolio to include a range of disease-state markers and other critical reagents for human health. By providing researchers with the high-quality reagents needed to study the Sudanese Ebolavirus, we hope to increase the likelihood that a successful vaccine can be developed in the future."

For further information about The Native Antigen Companyís Sudan Ebolavirus Boniface 1976 Glycoprotein, please visit:

https://thenativeantigencompany.com/products/ebola-virus-envelope-glycoprotein-gp-sudan/

https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON425

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    The Native Antigen Company. (2022, December 08). The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein. News-Medical. Retrieved on July 23, 2024 from https://www.news-medical.net/news/20221208/The-Native-Antigen-Company-expands-infectious-disease-portfolio-to-include-Sudan-Ebolavirus-Boniface-1976-Glycoprotein.aspx.

  • MLA

    The Native Antigen Company. "The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein". News-Medical. 23 July 2024. <https://www.news-medical.net/news/20221208/The-Native-Antigen-Company-expands-infectious-disease-portfolio-to-include-Sudan-Ebolavirus-Boniface-1976-Glycoprotein.aspx>.

  • Chicago

    The Native Antigen Company. "The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein". News-Medical. https://www.news-medical.net/news/20221208/The-Native-Antigen-Company-expands-infectious-disease-portfolio-to-include-Sudan-Ebolavirus-Boniface-1976-Glycoprotein.aspx. (accessed July 23, 2024).

  • Harvard

    The Native Antigen Company. 2022. The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein. News-Medical, viewed 23 July 2024, https://www.news-medical.net/news/20221208/The-Native-Antigen-Company-expands-infectious-disease-portfolio-to-include-Sudan-Ebolavirus-Boniface-1976-Glycoprotein.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The Native Antigen Company Strengthens Senior Team to Support Growing Product Portfolio